Quick Answer
AVAI BIO, INC. reported Total Revenue of $276.3 thousand for fiscal year 2023.
AVAI BIO, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $276.3K | — | — | — |
| Net Income | -$1.14M +46.3% |
-$2.13M -510.0% |
-$348.9K | — | -$248.0K -256.4% |
-$69.6K +11.0% |
| Total Assets | $224.7K -30.2% |
$322.0K +33.4% |
$241.5K -46.9% |
$454.7K -44.3% |
$816.3K +94.4% |
$420.0K +1275.9% |
| Cash and Equivalents | $81.1K +28744.5% |
$281.00 -99.7% |
$107.5K +222.8% |
$33.3K -44.9% |
$60.4K +121.1% |
$27.3K +26665.7% |
| Stockholders Equity | -$1.56M -6.6% |
-$1.47M -131.6% |
-$633.3K -56.1% |
-$405.6K -23.9% |
-$327.4K -768.8% |
-$37.7K +24.0% |
| R&D Expense | — | — | — | — | — | $27.0K |
| Operating Income | -$1.14M +46.3% |
-$2.13M -510.0% |
-$348.9K -375.8% |
$126.5K -58.1% |
$302.3K +334.4% |
$69.6K +189.0% |
| Gross Profit | — | — | -$40.5K -119.2% |
$210.8K +1374.8% |
-$16.5K +93.5% |
-$256.3K |
| Shares Outstanding | 137.36M +17.2% |
117.17M +204.3% |
38.50M +46.3% |
26.32M +0.1% |
26.28M +2369.9% |
1.06M -78.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$553.7K | -22.4% | -22.2% |
| Total Assets | December 31, 2025 | $172.9K | -1.1% | -25.3% |
| Cash and Equivalents | December 31, 2025 | $50.4K | +1541.8% | -45.2% |
| Stockholders Equity | December 31, 2025 | -$2.79M | -30.9% | -21.5% |
| R&D Expense | September 30, 2025 | $23.8K | — | — |
| Operating Income | December 31, 2025 | -$553.7K | -222.4% | -22.2% |
| Gross Profit | December 31, 2022 | -$71.5K | -124.5% | -1185.2% |
| Shares Outstanding | December 31, 2025 | 138.03M | +0.7% | +0.1% |
- AVAI BIO, INC. reported Total Revenue of $276.3 thousand for fiscal year 2023.
- AVAI BIO, INC. reported Net Income of -$1.14 million for fiscal year 2025.
- AVAI BIO, INC. showed an increase of +46.3% in Net Income compared to the prior fiscal year.
- AVAI BIO, INC. reported Total Assets of $224.7 thousand for fiscal year 2025.
- AVAI BIO, INC. showed a decrease of -30.2% in Total Assets compared to the prior fiscal year.
- AVAI BIO, INC. reported Cash and Equivalents of $81.1 thousand for fiscal year 2025.
- AVAI BIO, INC. showed an increase of +28744.5% in Cash and Equivalents compared to the prior fiscal year.
- AVAI BIO, INC. reported Stockholders Equity of -$1.56 million for fiscal year 2025.
- AVAI BIO, INC. showed a decrease of -6.6% in Stockholders Equity compared to the prior fiscal year.
- AVAI BIO, INC. reported R&D Expense of $27.0 thousand for fiscal year 2020.
- AVAI BIO, INC. reported Operating Income of -$1.14 million for fiscal year 2025.
- AVAI BIO, INC. showed an increase of +46.3% in Operating Income compared to the prior fiscal year.
- AVAI BIO, INC. reported Gross Profit of -$40.5 thousand for fiscal year 2023.
- AVAI BIO, INC. showed a decrease of -119.2% in Gross Profit compared to the prior fiscal year.
- AVAI BIO, INC. reported Shares Outstanding of 137.36 million shares for fiscal year 2025.
- AVAI BIO, INC. showed an increase of +17.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: